Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer

Glemser, P. A.; Rotkopf, L. T.; Ziener, C. H.; Beuthien-Baumann, B.; Weru, V.; Kopp-Schneider, A.; Schlemmer, H. P.; Dimitrakopoulou-Strauss, A.; Sachpekidis, C.

doi:10.1186/s40644-022-00489-9

Cancer Imaging

Table 2 Characteristics of the enrolled patients

From: Hybrid imaging with [⁶⁸Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer

Patient number	Age (years)	PSA at examination (ng/ml)	Previous treatment	Gleason Score	Injected activity (MBq)	Number of lesions (Localisation)
Patient number	Age (years)	PSA at examination (ng/ml)	Previous treatment	Gleason Score	Injected activity (MBq)	PET-CT	PET-MRI	MRI
1	59	0.6	RPx	n.a.	144	0	0^a	0
2	79	4.8	RPx + RT + ADT	9	145	2 (LN)	2 (LN)^a	0
3	59	7.18	RT	7	141	1 (LR)	1 (LR)^a	0
4	76	4.95	HIFU + ADT	9	105	2 (LR, LN)	1 (LR)^b	1 (LR)
5	62	0.39	RPx	8	121	1 (LN)	1 (LN)^a	0
6	74	4.2	RPx	n.a.	235	> 20 (LN, B)	> 20 (LN, B)^a	9 (LN)
7	56	2.4	RPx	7	264	0	1 (O)^c	1 (O)
8	73	0.68	RPx	7	252	1 (LN)	0^c	0
9	59	0.2	RPx	n.a.	265	0	0^a	0
10	71	1.7	RPx	7	107	10 (LN)	14 (LN)^b	6 (LN)
11	67	0.58	RPx + RT	7	98	2 (LN)	1 (LN)^b	0
12	79	0.46	RPx	9	255	0	0^a	0
13	53	2.9	RPx + RT + ADT	9	214	1 (B)	1 (B)^a	0
14	75	4.3	RPx + RT + ADT	n.a.	242	5 (LN)	5 (LN)^a	0
15	77	2.0	RPx	7	135	0	1 (O)^c	1 (O)
16	61	0.45	RPx	7	199	0	0^a	0
17	66	10.0	Electrocoagulation of the prostate	7	250	> 20 (LN)	> 20 (LR, LN)^b	8 (LR, LN)
18	71	0.39	RPx + RT	7	252	0	0^a	0
19	66	1.2	RPx + ADT	n.a.	165	0	1 (LR)^c	1 (LR)
20	64	4.5	RPx + RT	8	165	0	0^a	0
21	68	1.2	RT + ADT	9	154	1 (LR)	1 (LR)^a	1 (LR)
22	69	4.73	RPx	8	150	1 (LN)	1 (LN)^a	1 (LN)
23	74	1.68	RPx	7	140	2 (B)	2 (B)^a	2 (B)
24	70	1.5	RPx + RT	7	196	8 (LN, B)	8 (LN, B)^a	2 (LN, B)
25	59	1.15	RPx + RT	6	172	1 (LN)	1 (LN)^a	0
26	77	0.29	RPx + RT + ADT	9	224	7 (LN)	7 (LN)^a	2 (LN)
27	75	0.2	RPx	7	228	1 (LN)	0^c	0
28	68	1.18	RPx + RT	7	211	0	0^a	0
29	70	25.9	RPx + ADT	7	199	18 (LN)	18 (LN)^a	3 (LN)
30	56	2.0	RPx + RT	n.a.	197	1 (LN)	1 (LN)^a	0
31	66	3.9	RPx + RT + ADT	n.a.	272	1 (LN)	1 (LN)^a	0
32	81	0.8	RPx + RT	7	149	1 (B)	1 (B)^a	0
33	75	4.1	RT	n.a.	222	3 (LN)	3 (LN)^a	2 (LN)
34	77	2.02	RPx + ADT	9	287	5 (LN)	3 (LR, LN)^b	1 (LR)
35	69	7.1	RPx + RT + ADT	n.a.	144	13 (LN)	13 (LN)^a	0
36	70	2.8	RPx + RT + ADT	n.a.	235	3 (LN)	3 (LN)^a	2 (LN)
37	49	1.73	RPx	7	141	1 (LR)	1 (LR)^a	1 (LR)
38	63	1.6	RPx	n.a.	117	0	1 (LN)^c	1 (LN)
39	69	12.15	RPx	7	199	0	0^a	0
40	71	0.35	RPx	7	217	0	0^a	0
41	71	0.54	RPx + RT	7	259	0	0^a	0
42	69	3.6	RPx	n.a.	198	3 (LN)	2 (LN)^b	1 (LN)
43	64	0.15	RPx	7	71	0	0^a	0
44	61	1.0	RPx	9	180	1 (LN)	1 (LN)^a	1 (LN)
45	56	0.67	RPx	7	240	1 (LN)	2 (LN)^b	2 (LN)
46	66	6.2	RPx + ADT	9	247	1 (LN)	1 (LN)^a	1 (LN)
47	70	0.07	RPx	8	238	0	0^a	0
48	60	1.09	RPx + RT	8	166	0	0^a	0
49	71	0.2	RPx	7	250	0	0^a	0
50	74	0.31	RPx + RT	8	256	0	0^a	0
51	67	3.5	RPx + ADT	7	156	5 (LN)	4 (LN)^b	0
52	60	0.7	RPx	7	143	4 (LN)	4 (LN)^a	2 (LN)
53	79	1.76	RPx + RT	7	170	1 (B)	1 (B)^a	0

n.a. Not available, RPx Radical prostatectomy, RT Radiotherapy, ADT Androgen deprivation therapy, HIFU High-intensity focused ultrasound, LN Lymph node metastasis, LR Local recurrence, B Bone metastasis, O Other organ metastases
^aPatients with concordant findings in PET/MRI and PET/CT
^bPatients with vastly concordant findings in PET/MRI and PET/CT that would potentially lead to no treatment changes based on the different imaging results
^cPatients with significant differences between PET/MRI and PET/CT that would potentially lead to treatment changes based on the different imaging results

Back to article page

ISSN: 1470-7330

Contact us

Submission enquiries: alyzza.javate@springernature.com
General enquiries: info@biomedcentral.com